Clinical trial NCT05162989: iCare HOME2 Clinical Trial
Official title: iCare HOME2 Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intraocular Pressure
Glaucoma
Lead sponsor: Icare Finland Oy
Sponsor class: INDUSTRY
First posted: 2021-12-20
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this clinical study is to provide information about the variability of the intraocular pressure (IOP) self-measurements with the iCare HOME2 tonometer in comparison to the variability of the IOP measurements with the reference tonometer (iCare IC200), over a wide range of IOP values.

Detailed description: The clinical study is planned to estimate the variability of the IOP measurement of iCare HOME2 and IC200. In the study, the subjects will learn to operate the iCare HOME2 tonometer independently by using the labeling materials provided to them. Once they learn to operate the tonometer, subjects will take three self-measurements on the selected eye both in sitting and supine position.

The variability of the measurement results taken with iCare HOME2 will be compared to the variability of the measurement results taken with iCare IC200 by using the recorded results from the study subjects.

Eligibility criteria: Inclusion Criteria:

* Glaucoma patients having confirmed optic nerve damage with visual field defects consistent with the glaucomatous optic neuropathy or
* Glaucoma-suspects being followed because of elevated IOP, and/or because of other risk factors for developing glaucoma or optic nerve damage.

Exclusion Criteria:

* Active ocular infection (e.g., pink eye or infectious conjunctivitis)
* Recent trauma to the eye including corneal laceration or corneal/scleral perforation
* Disabling arthritis or difficulty handling the tonometer
* Severe difficulty in opening the eyes including abnormal contractions or twitches of the eyelid (blepharospasm)
* Involuntary, rapid, and repetitive eye movements (nystagmus)
* Low uncorrected near visual acuity of 20/200 or below
* Significant glaucomatous central field loss
* Only one functional eye
* Poor or off-center visual fixation
* Poor hearing and/or communicates using sign language
* Keratoconus (or other corneal disorder)
* Congenitally small eye (microphthalmos)
* Enlarged eyeball from the childhood glaucoma (buphthalmos)
* Previous experience using or interacting with the HOME tonometer during usability tests or clinical trials
* Any affiliation with Icare and its employees
* High corneal astigmatism (\>3d)
* History of prior invasive corneal surgery including corneal laser surgery less than six months ago (e.g., LASIK, LASEK, Smile)
* Corneal scarring
* Very thick or very thin corneas (central corneal thickness greater than 600 μm or less than 500 μm)
* Cataract extraction within the last 2 months
* Wearing contact lenses during the study

Primary outcomes:
measure: Repeatability of IOP measurements
timeFrame: Through study completion, an average of 1-2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: East West Eye Institute
state: California
Study officials:
affiliation: East West Eye Institute
name: Michelle A Sato, MD
role: PRINCIPAL_INVESTIGATOR
References: